Genmab and AbbVie’s Epkinly win, a rush of deals, Sarepta’s turnaround hopes, more

Data ReadoutpositiveEpkinlyPositive

AI Analysis

Summary

Genmab and AbbVie's Epkinly demonstrated positive data that could support expanded approval in diffuse large B cell lymphoma. Novartis acquired China's Abogen Biosciences for nearly $8 billion in mRNA drug development.

Outcome Details

New data for Epkinly wowed analysts and could set the partners up for an expanded approval in diffuse large B cell lymphoma

Importance:7/10

Sentiment:

0.70

Epkinlybispecific antibodyDLBCLexpansion approvalmRNA acquisitiondeal activity

Related Companies

$GMAB $ABBV $SRPT $NVS

Read the original article

Published by BioSpace on October 7, 2026 9:42 AM

Read Original